The portfolio principally allocates its capital to common equities. A minimum of 80% of its assets are typically invested in enterprises primarily dedicated to the research, development, manufacture, and distribution of biotechnological products, services, and processes, or those entities positioned to significantly benefit from scientific and technological advancements in biotechnology. Holdings encompass both domestic and international companies.